Search

Your search keyword '"Bhella, Sita"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Bhella, Sita" Remove constraint Author: "Bhella, Sita" Journal blood Remove constraint Journal: blood
25 results on '"Bhella, Sita"'

Search Results

1. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma

3. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

4. Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

5. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

6. Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

8. Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

9. Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

11. Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

12. Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

14. Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

15. Characterization of Clonal Hematopoietic of Indeterminate Potential (CHIP) Mutations in an Imid-Naïve Multiple Myeloma (MM) Autologous Stem Cell Transplant (ASCT) Population: First Results from a Pre-Transplant Time Point in a Prospective, Longitudinal Study

16. Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial

17. Prolonged Duration of Systemic Immunosuppression after Allogeneic Hematopoietic Cell Transplantation Associates with the Use of Peripheral Blood Stem Cells, Severe Grade of Chronic Gvhd, Progressive Type Onset of Chronic Gvhd, Grade 2-4 Acute Gvhd and Older Age, but Not with T-Cell Depletion or Conditioning Regimen

18. Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

19. Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review

20. Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion

22. FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

25. The Addition of Rituximab and/or Alpha-Interferon to High Dose Chemotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed Follicular Lymphoma Produces Durable Progression Free Survival and Molecular Remissions

Catalog

Books, media, physical & digital resources